S'abonner

Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus - 24/01/23

Doi : 10.1016/j.diabet.2022.101393 
Szu-Yuan Wu a, b, c, d, e, f, g, Wan-Ming Chen a, b, Yi-Chan Chen h, Ming-Feng Chiang i, Ming-Che Lee j, k, Ruey-Shyang Soong j, k,
a 1Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, New Taipei City, Taiwan 
b Artificial Intelligence Development Center, Fu Jen Catholic University, New Taipei City, Taiwan 
c Department of Food Nutrition and Health Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan 
d Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan 
e Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan 
f Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan 
g Centers for Regional Anesthesia and Pain Medicine, Taipei Municipal Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 
h Department of General Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan 
i Division of Gastroenterology and Hepatology, Department of Internal Medicine, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan 265, Taiwan 
j Department of Surgery, Taipei Municipal Wanfang Hospital, Taipei, Taiwan 
k College of Medicine, Taipei Medical University, Taipei, Taiwan 

Corresponding author at: Division of Transplantation, Department of Surgery, Taipei Municipal Wanfang Hospital, Taipei, Taiwan.Division of Transplantation, Department of SurgeryTaipei Municipal Wanfang HospitalTaipeiTaiwan

Highlights

Question: H1-antihistamines (AHs) may exert protective effects against cancer. Does any protective effect of AHs on hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection?
Findings: The adjusted hazard ratios for AH users with diabetes (compared with AH nonusers with diabetes) were significantly associated with decreased HCC incidence, regardless of age, sex, comorbidities, medications, diabetes medications, and diabetes severity.
Meaning: AH use may reduce HCC in patients with T2DM in a dose-dependent manner.

Le texte complet de cet article est disponible en PDF.

Abstract

Purpose

H1-antihistamines (AHs) may exert protective effects against cancer. We investigated the association of AH use with hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

Methods

The data of patients with T2DM enrolled from Taiwan's National Health Insurance Research Database were examined for the period of January 1, 2008, to December 31, 2018. We used the Kaplan–Meier method and Cox proportional hazards regression to evaluate the AH use–HCC risk association.

Results

After 1:1 propensity score matching was performed, the two cohorts were each divided into AH users (n = 47,990) and nonusers (n = 47,990). The risk of HCC was significantly lower in AH users than in AH nonusers (adjusted hazard ratio [aHR]: 0.55 95% confidence interval [95% CI], 0.46 to 0.67; IRR: 0.70; 95% CI, 0.60 to 0.84), respectively. The dose–response relationship between AH use and HCC risk was also observed (aHRs: 0.58, 0.56, 0.50, and 0.41 for 28–35, 36–49, 50–77, and >77 cumulative defined daily doses of AH, respectively).

Conclusion

AH use can reduce HCC risk in T2DM patients without HBV or HCV infection in a dose-dependent manner.

Le texte complet de cet article est disponible en PDF.

Keywords : H1-Antihistamines, Hepatocellular Carcinoma, incidence rate ratio, Type 2 Diabetes Mellitus, dose-dependent

Abbreviations : aHR, CI, NSAID, aDCSI, AH, cDDD, IQR, SD, N, SMD, HR, IR, IRR, HCC, T2DM, HBV, HCV, IGT, PSM, NHI, NHIRD, IGF-1, TNF-α, IL-6


Plan


© 2022  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 49 - N° 1

Article 101393- janvier 2023 Retour au numéro
Article précédent Article précédent
  • Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans: A prospective cohort study
  • Julie Pires Da Silva, Matthieu Wargny, Jérémy Raffin, Mikaël Croyal, Thibaut Duparc, Guillaume Combes, Annelise Genoux, Bertrand Perret, Bruno Vellas, Sophie Guyonnet, Claire Thalamas, Dominique Langin, Cédric Moro, Nathalie Viguerie, Yves Rolland, Philipe de Souto Barreto, Bertrand Cariou, Laurent O. Martinez, the MAPT/DSA Group
| Article suivant Article suivant
  • Physical activity and diabetes mortality in people with type 2 diabetes: a prospective cohort study of 0.5 million US people
  • Maria Reyes Beltran-Valls, Verónica Cabanas-Sánchez, Kabir P. Sadarangani, Fernando Rodríguez-Artalejo, Diego Moliner-Urdiales, David Martínez-Gómez

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.